EP4023647A4 - Imidazopyridinlderivate und pharmazeutische zusammensetzung damit als wirkstoff - Google Patents

Imidazopyridinlderivate und pharmazeutische zusammensetzung damit als wirkstoff Download PDF

Info

Publication number
EP4023647A4
EP4023647A4 EP20857012.7A EP20857012A EP4023647A4 EP 4023647 A4 EP4023647 A4 EP 4023647A4 EP 20857012 A EP20857012 A EP 20857012A EP 4023647 A4 EP4023647 A4 EP 4023647A4
Authority
EP
European Patent Office
Prior art keywords
same
pharmaceutical composition
active ingredient
imidazopyridine derivative
imidazopyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20857012.7A
Other languages
English (en)
French (fr)
Other versions
EP4023647A1 (de
Inventor
Jae Won Lee
Do Hyun Son
Nam Sook Kang
Sung Wook Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsd Life Sciences Co Ltd
Original Assignee
Tsd Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsd Life Sciences Co Ltd filed Critical Tsd Life Sciences Co Ltd
Publication of EP4023647A1 publication Critical patent/EP4023647A1/de
Publication of EP4023647A4 publication Critical patent/EP4023647A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP20857012.7A 2019-08-30 2020-08-31 Imidazopyridinlderivate und pharmazeutische zusammensetzung damit als wirkstoff Pending EP4023647A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190107013 2019-08-30
PCT/KR2020/011663 WO2021040502A1 (ko) 2019-08-30 2020-08-31 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물

Publications (2)

Publication Number Publication Date
EP4023647A1 EP4023647A1 (de) 2022-07-06
EP4023647A4 true EP4023647A4 (de) 2023-08-16

Family

ID=74683886

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20857012.7A Pending EP4023647A4 (de) 2019-08-30 2020-08-31 Imidazopyridinlderivate und pharmazeutische zusammensetzung damit als wirkstoff

Country Status (9)

Country Link
US (1) US20220396575A1 (de)
EP (1) EP4023647A4 (de)
JP (1) JP7345220B2 (de)
KR (1) KR102459614B1 (de)
CN (1) CN114555595B (de)
AU (1) AU2020337720B2 (de)
CA (1) CA3148490A1 (de)
WO (1) WO2021040502A1 (de)
ZA (1) ZA202201888B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220122879A (ko) * 2021-02-26 2022-09-05 주식회사 티에스디라이프사이언스 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068483A2 (en) * 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
WO2010148197A1 (en) * 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2015092592A1 (en) * 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US20160096834A1 (en) * 2014-10-06 2016-04-07 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20100190777A1 (en) * 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009029609A1 (en) * 2007-08-27 2009-03-05 Wyeth Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2010003048A1 (en) * 2008-07-03 2010-01-07 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
EA021437B1 (ru) 2009-09-29 2015-06-30 Глэксо Груп Лимитед Соединения, ингибирующие lrrk2 киназную активность
AU2012267556B9 (en) * 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
KR102516162B1 (ko) 2013-12-02 2023-03-29 가부시키가이샤 한도오따이 에네루기 켄큐쇼 표시 장치 및 그 제조방법
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
MX2017015357A (es) * 2015-06-29 2018-03-16 Merck Patent Gmbh Compuestos inhibidores de serina/treonina-proteina cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y usos de los mismos.
MX2018009773A (es) * 2016-02-23 2018-11-29 Padlock Therapeutics Inc Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
KR102548543B1 (ko) * 2017-01-11 2023-06-29 아킬리온 에이비 야누스 키나아제 억제제로서 신규한 아미노-이미다조피리딘 유도체 및 그의 약제학적 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068483A2 (en) * 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
WO2010148197A1 (en) * 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2015092592A1 (en) * 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US20160096834A1 (en) * 2014-10-06 2016-04-07 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GALLO KATHLEEN A ET AL: "Therapeutic potential of targeting mixed lineage kinases in cancer and inflammation", PHARMACOLOGY & THERAPEUTICS, ELSEVIER, GB, vol. 207, 18 December 2019 (2019-12-18), XP086060323, ISSN: 0163-7258, [retrieved on 20191218], DOI: 10.1016/J.PHARMTHERA.2019.107457 *
See also references of WO2021040502A1 *
XIAO DING ET AL: "Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present)", EXPERT OPINION ON THERAPEUTIC PATENTS, 18 February 2020 (2020-02-18), GB, pages 1 - 12, XP055671253, ISSN: 1354-3776, DOI: 10.1080/13543776.2020.1729354 *

Also Published As

Publication number Publication date
US20220396575A1 (en) 2022-12-15
CN114555595A (zh) 2022-05-27
KR102459614B1 (ko) 2022-10-31
KR20210028122A (ko) 2021-03-11
AU2020337720B2 (en) 2024-02-15
JP2022547436A (ja) 2022-11-14
WO2021040502A1 (ko) 2021-03-04
CN114555595B (zh) 2023-12-26
JP7345220B2 (ja) 2023-09-15
CA3148490A1 (en) 2021-03-04
AU2020337720A1 (en) 2022-03-03
EP4023647A1 (de) 2022-07-06
ZA202201888B (en) 2023-03-29

Similar Documents

Publication Publication Date Title
EP3604306A4 (de) Makrocyclisches derivat von pyrazol[3,4-d]pyrimidin-3-on, pharmazeutische zusammensetzung und verwendung davon
EP3604301A4 (de) 4-pyridonverbindung oder salz davon und pharmazeutische zusammensetzung und formulierung damit
EP3753936A4 (de) Pyridonderivat, zusammensetzung davon und verwendung davon als arzneimittel gegen grippe
EP3638248A4 (de) Konjugate von pharmazeutischen wirkstoffen
EP3613419A4 (de) Pharmazeutische zusammensetzung mit indirubinderivat als wirkstoff
EP3312175A4 (de) Heteroarylderivat oder pharmazeutisch unbedenkliches salz davon, herstellungsverfahren dafür, und pharmazeutische zusammensetzung zur prävention oder behandlung von erkrankungen, die mit pi3-kinasen assoziiert sind, die diese als wirkstoff enthalten
EP4051241A4 (de) Pharmazeutische zusammensetzungen aus albumin und rapamycin
EP3762392A4 (de) Thienopyridinderivate und pharmazeutische zusammensetzung damit
EP3604304A4 (de) Pyrrolo-pyridin-derivat-verbindung, verfahren zur herstellung und pharmazeutische zusammensetzung damit zur prävention oder behandlung von proteinkinase-verwandten krankheiten
EP4005591A4 (de) Antineoplastische kombinierte pharmazeutische zusammensetzung und ihre verwendung
EP4073071A4 (de) Verwendung und pharmazeutische zusammensetzung von phenylisoxazolylmethylen-naphthalen-ether-derivaten
EP3827810A4 (de) Kosmetische zusammensetzung mit aus galactomyces gewonnenem exosom als aktivem bestandteil
EP4008718A4 (de) Heteroarylamidopyridinolderivate und pharmazeutische zusammensetzungen, die diese umfassen, zur vorbeugung oder behandlung von autoimmunerkrankungen
EP3929198A4 (de) Heterocyclische verbindung, pharmazeutische zusammensetzung damit, verfahren zu ihrer herstellung und ihre verwendung
EP3915986A4 (de) Heteroarylderivate und pharmazeutische zusammensetzung damit als wirkstoff
EP3480186A4 (de) Neuartiges arylethanderivat und pharmazeutische zusammensetzung damit als wirkstoff
EP4166155A4 (de) Zusammensetzung mit pentapeptid als wirkstoff
ZA202201888B (en) Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
EP4015042A4 (de) Pharmazeutische zusammensetzung mit antimykotikum als wirkstoff
EP3976093A4 (de) Antibakterielle pharmazeutische zusammensetzungen mit breitem spektrum mit lysozym und verfahren zur verwendung davon
EP3946296A4 (de) Pharmazeutische formulierung mit verlängerter freisetzung
EP2722322B8 (de) 1,3-di-oxo-inden-derivat, pharmazeutisch zulässiges salz und optisches isomer davon, herstellungsverfahren dafür und pharmazeutische zusammensetzung mit diesem derivat als antiviralem wirkstoff
EP4048276A4 (de) Feste pharmazeutische formulierungen mit ticagrelor
EP3626703A4 (de) Neuartige verbindung und pharmazeutische zusammensetzung damit als wirkstoff
EP3760627A4 (de) Imidderivat und bakterizid damit als wirkstoff

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230717

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/497 20060101ALI20230711BHEP

Ipc: A61K 31/5377 20060101ALI20230711BHEP

Ipc: A61K 31/437 20060101ALI20230711BHEP

Ipc: A61P 31/16 20060101ALI20230711BHEP

Ipc: A61P 1/16 20060101ALI20230711BHEP

Ipc: A61P 25/28 20060101ALI20230711BHEP

Ipc: A61P 35/00 20060101ALI20230711BHEP

Ipc: C07D 471/04 20060101AFI20230711BHEP